Feed Symbols: OTSKY

Akebia Therapeutics Inc (NASDAQ:AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19…

Here's a roundup of top developments in the biotech space over the last 24 hours:

The FDA has issued a complete response letter (CRL) to Akebia Therapeutics Inc’s (NASDAQ:AKBA) marketing application (NDA) for vadadustat for anemia due…

Akebia Therapeutics Inc (NASDAQ:AKBA) and its collaborator Otsuka Holdings (OTC:OTSKY) have announced that the FDA has accepted to review vadadustat’s marketing application for…